Modality
siRNA
MOA
BCL-2i
Target
PRMT5
Pathway
Apoptosis
Schizophrenia
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
Nov 2021
→ Nov 2029
Phase 1Current
NCT08924117
2,998 pts·Schizophrenia
2021-11→2029-11·Not yet recruiting
2,998 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-043.6y awayInterim· Schizophrenia
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2029-11-04 · 3.6y away
Schizophrenia
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08924117 | Phase 1 | Schizophrenia | Not yet recr... | 2998 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Tezecilimab | Takeda | NDA/BLA | Tau |